Savara (SVRA) Research & Development (2010 - 2026)
Savara (SVRA) posted quarterly Research & Development of $23.4 million for Q1 2026, up 22.13% year-over-year from $19.2 million in Q1 2025, and up 11.94% quarter-over-quarter from $20.9 million in Q4 2025.
Savara (SVRA) Research & Development (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Research & Development for 17 consecutive years, with $23.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 22.13% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $85.6 million (up 6.55% YoY), while the FY2025 annual figure was $81.4 million, up 4.33% from the prior year.
- Research & Development improved to $23.4 million in Q1 2026 per SVRA's latest filing, from $20.9 million in the prior quarter.
- Across five years, Research & Development topped out at $23.4 million in Q1 2026 and bottomed at $5.7 million in Q1 2022.
- Historically, Research & Development has averaged $15.0 million across 5 years, with a median of $16.8 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development slipped 25.1% — and 2024, when it surged 97.7%.
- Savara's Research & Development stood at $7.6 million in 2022, then jumped by 67.14% to $12.7 million in 2023, then surged by 82.76% to $23.3 million in 2024, then declined by 10.27% to $20.9 million in 2025, then grew by 11.94% to $23.4 million in 2026.
- Business Quant data shows SVRA's Research & Development at $23.4 million in Q1 2026, $20.9 million in Q4 2025, and $20.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 21.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.95 Mn |
| Mar 31, 2026 | 23.40 Mn |
| Dec 31, 2025 | 20.90 Mn |
| Sep 30, 2025 | 20.59 Mn |
| Jun 30, 2025 | 20.75 Mn |
| Mar 31, 2025 | 19.16 Mn |
| Dec 31, 2024 | 23.29 Mn |
| Sep 30, 2024 | 20.31 Mn |
| Jun 30, 2024 | 17.62 Mn |
| Mar 31, 2024 | 16.81 Mn |
| Dec 31, 2023 | 12.75 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 8.91 Mn |
| Mar 31, 2023 | 8.74 Mn |
| Dec 31, 2022 | 7.63 Mn |
| Sep 30, 2022 | 8.15 Mn |
| Jun 30, 2022 | 6.42 Mn |
| Mar 31, 2022 | 5.68 Mn |
| Dec 31, 2021 | 7.62 Mn |
| Sep 30, 2021 | 6.53 Mn |